First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Sources of information and study methodology
Close this folder3. Dissemination and uptake of the Guidelines
View the documentThe development stage: September 1994 - May 1996
View the documentThe launch: May 1996
View the documentAfter May 1996: dissemination of the Guidelines
View the documentOther publications about drug donations
View the documentConferences at which the Guidelines were discussed
View the documentInternational organizations subscribing to the Guidelines
View the documentCountries and national organizations that have adapted or adopted the Guidelines
View the documentOther country studies on drug donations
Open this folder and view contents4. Basic characteristics of drug donations
Open this folder and view contents5. Practical benefits as a result of the Guidelines
View the document6. Drug donations which were hampered, delayed or cancelled
Open this folder and view contents7. Experiences and opinions regarding the 12-month shelf-life requirement
Open this folder and view contents8. Other suggestions to improve the Guidelines
Open this folder and view contents9. How could donation practice be further improved?
View the document10. Summary of recommendations
View the document11. Postscript
View the documentReferences
 

3. Dissemination and uptake of the Guidelines

In this chapter an overview is given of the different ways in which donors, consolidators and recipients have reacted to the issuing of the Guidelines in May 1996. Apart from being valuable in the discussion on the impact of the Guidelines in improving donation practices, this part of the review constitutes an interesting case study of the impact of a portion of WHO's work.

to previous section to next section
 

Last updated: May 3, 2013